Business Standard

Remdesivir improves time to recovery in Covid-19 patients, says new study

The researchers, including those from the New York University in the US, found that remdesivir was most beneficial for hospitalised patients with severe disease requiring supplemental oxygen

The government is now trying to understand how long it will take before the drug’s production can start in India
Premium

Findings about benefits in other patient subgroups were less conclusive in this analysis

Agencies
Remdesivir, the antiviral drug under clinical trials for treatment against novel coronavirus infection, is superior to the standard of care given to Covid-19 patients, according to a new study.

The analysis, published in the New England Journal of Medicine, is based on data from the Adaptive Covid-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) in the US, news agency PTI reported.

In the randomised, controlled trial, clinicians enrolled adults hospitalised with Covid-19 who showed infection in the lower respiratory tract and suffered from moderate to severe disease.

The researchers, including those from the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 27 2020 | 1:26 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com